RC 3095
Alternative Names: D 21663; RC-3095Latest Information Update: 08 Aug 2024
At a glance
- Originator Tulane University
- Developer AEterna Zentaris Inc
- Class Antineoplastics
- Mechanism of Action Gastrin-releasing peptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Solid tumours
Most Recent Events
- 06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
- 04 Aug 2005 This compound is still in active development for Cancer
- 01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris